Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013–2017: A nationwide CAS registry analysis from the I-O Optimise initiative-Reference-Cited by-同舟云学术

Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013–2017: A nationwide CAS registry analysis from the I-O Optimise initiative

Published:2021-12 Issue: Volume:162 Page:185-193
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Baas Paul,Daumont Melinda J.,Lacoin Laure,Penrod John R.,Carroll Robert,Venkatesan Sudhir,Ubhi Harveen,Calleja Alan,Snee Michael

Funder

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference42 articles.

1. International Agency for Research on Cancer, GLOBOCAN 2020: Mesothelioma 2020. https://gco.iarc.fr/today/data/factsheets/cancers/18-Mesothelioma-fact-sheet.pdf. (Accessed March 2021).

2. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Baas;Ann. Oncol.,2015

3. Malignant mesothelioma in south east England: clinicopathological experience of 272 cases;Yates;Thorax,1997

4. Routes of asbestos exposure and the development of mesothelioma in an English region;Howel;Occup. Environ. Med.,1997

5. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems;Edwards;Thorax,2000

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient characteristics, treatment patterns, and survival outcomes for patients with malignant pleural mesothelioma in Denmark between 2011 and 2018: a nationwide population-based cohort study;Acta Oncologica;2024-08-08

2. Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04–2021) trial;Lung Cancer;2024-08

3. Comprehensive Pulmonary Rehabilitation for Patients with Malignant Pleural Mesothelioma: A Feasibility Pilot Study;Cancers;2024-05-26

4. Mesothelioma-Associated Fibroblasts Modulate the Response of Mesothelioma Patient-Derived Organoids to Chemotherapy via Interleukin-6;International Journal of Molecular Sciences;2024-05-14

5. Detailed clinical course of a patient with rapidly progressing sarcomatoid pleural mesothelioma without p16 deletion with systemic haematogenous metastasis to soft tissues;BMJ Case Reports;2024-02